Dept of Medicine, University of Cape Town, Cape Town, South Africa.
Dept of Medicine, Touro College of Osteopathic Medicine, Middletown, New York, USA.
Clin Cardiol. 2021 Mar;44(3):322-331. doi: 10.1002/clc.23572. Epub 2021 Feb 17.
The amyloidoses are a family of diseases in which misfolded precursor proteins aggregate to form amyloid and deposit in body tissues. A very serious yet underrecognized form of this disease is cardiac amyloidosis, in which amyloid deposits into the extracellular space of the myocardium, resulting in thickening and stiffening of ventricular walls with resultant heart failure and conductive dysfunction. This review provides a discussion of the pathogenesis and clinical presentation of cardiac amyloidosis subtypes, as well as an up-to-date approach to diagnosis and treatment. Significant progress has been made in recent years regarding diagnosis and treatment of this condition, but prognosis remains heavily reliant on early detection of the disease. Two types of precursor protein are responsible for most cardiac amyloidosis cases: transthyretin amyloid, and immunoglobulin-derived light chain amyloid. An early diagnosis of cardiac amyloidosis can allow for novel treatment modalities to be initiated with the potential to improve prognosis.
淀粉样变性是一组疾病,其中错误折叠的前体蛋白聚集形成淀粉样物质并在体内组织中沉积。这种疾病的一种非常严重但认识不足的形式是心脏淀粉样变性,其中淀粉样物质沉积在心外膜的细胞外空间,导致心室壁变厚和僵硬,从而导致心力衰竭和传导功能障碍。本文讨论了心脏淀粉样变性亚型的发病机制和临床表现,以及最新的诊断和治疗方法。近年来,在这种疾病的诊断和治疗方面取得了重大进展,但预后仍然严重依赖于疾病的早期发现。两种类型的前体蛋白是导致大多数心脏淀粉样变性的原因:转甲状腺素蛋白淀粉样变性和免疫球蛋白衍生的轻链淀粉样变性。心脏淀粉样变性的早期诊断可以启动新的治疗方法,有可能改善预后。